文章摘要

文章信息/Info

Title:: Effect of Tirofiban on TIMI flow in patients with acute coronary syndrome

作者:: 夏豪; 谭安安; 周桃; 胡波; 武汉大学人民医院心内科, 湖北武汉 430060

Author(s):: XIA Hao; TAN Anan; ZHOU Tao; HU Bo; Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China

关键词:: 盐酸替罗非班; 冠脉综合征; 急性; 冠状动脉血管造影; 选择性

Keywords:: tirofiban; acute coronary syndrome; selective coronary angiography

分类号:: R541.4

DOI:: -

文献标识码:: A

摘要:: 目的分析 GPⅡb/Ⅲa受体拮抗剂盐酸替罗非班对急性冠脉综合征（ACS）患者心肌梗死溶栓试验(TIMI)血流的影响。方法选择急诊入院的ACS患者57例，分为试药组（盐酸替罗非班）29例和对照组28例。收集所有病例的临床和冠状动脉造影资料，观察两组TIMI血流情况。结果试药组梗死相关血管TIMI血流分级显著提高，试药组达Ⅰ级以上血流者比例显著高于对照组（97% vs 64%，P<0.01）；对照组完全闭塞者比例显著高于试药组（36% vs 3%,P<0.01）。结论盐酸替罗非班可以改善ACS患者梗死相关血管TIMI血流。

Abstract:: AIM To evaluate the effect of Tirofiban on TIMI flow in patients with acute coronary syndrome (ACS). METHODS Fiftyseven patients with ACS who would have selective coronary angiography (SCA) were randomly divided into two groups: Tirofiban+SCA group (n=29) and the SCA group (n=28), and TIMI flow was examined angiographically. RESULTS A greater percentage of TIMI ≥1 flow was achieved in Triofiban+SCA group compared with that in SCA group (97% vs 64%, P<0.05). The percentage of TIMI 0 flow was significantly higher in SCA group compared with that in Tirofiban+SCA group (36% vs 3%, P<0.01). CONCLUSION Tirofiban improves TIMI flow of IRA in patients with ACS．

参考文献/References

［1］ Lefkovits J，Plow EF，Topol EJ．Platelet glycoproteinⅡb/Ⅲa receptor in cardiovascular medicine［J］．N Engl J Med，1995，332(23)：1553-1558．

［2］ Montalescot G，Barragan P，Wittenbery O，et al．Platelet glycoprotein Ⅱb/Ⅲa inhibition with coronary stenting for acute myocardial infarction［J］．N Eng J Med，2001，344(25):1895-1903．

［3］ Lee DP，Herity NA，Hiatt BL，et al．Adjunctive platelet glycoprotein Ⅱb/Ⅲa inhibition with tirofiban before primary angioplasty improves angiographic outcome:Results of the tirofiban give in the Emergency room before primary angioplasty(TIGERPA)pilot trial［J］．Circulation,2003，107(11)：1497-1501．

［4］ Rasoul S,Ottervanger JP, de Boer MJ,et al. A comparison of dual vs. triple antiplatelet therapy in patients with nonSTsegment elevation acute coronary syndrome: results of the ELISA2 trial［J］. Eur Heart J,2006 ,27(12):1401-1407.

［5］陈灏珠.实用内科学［M］.第12版.北京:人民卫生出版社，2005:1467-1492

.［6］ The TIMI Study Group．The thrombolysis in myocardial infarction(TIMI)trial. phaseⅠfindings. TIMI Study Group［J］．N Engl Med，1985，312(14)：932-936．

［7］邹阳春. 急性冠脉综合征［J］.中国医药导刊，2005，7(1):73-78.

［8］ Elmouchi DA，Bates ER．Platelet glycoprotein Ⅱb/Ⅲa inhibitor therapy in nonST segment elevation acute coronary syndromes［J］．Minerva Cardioangiol，2003，51(5)：547-560.

［9］ Shen YT，Wiedmann RT，Lynch JJ Jr，et al．Platelet glycolprotein Ⅱb/Ⅲa receptor inhibitor preserves coronary flow reserve during progressive coronary arteriostenosis in swine［J］. Arterioscler Thromb Vasc Biol，2000，20(10)：2309-2315．

［10］徐邦牢，贝春花，黎镇赐，等.急性冠脉综合征早期盐酸替罗非班治疗对血清可溶性CD40配体水平的影响［J］.中国心血管杂志，2006，11(2):99-100,108.

我们的网站为什么显示成这样？

盐酸替罗非班对急性冠脉综合征梗死相关血管TIMI血流的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics